NASDAQ:OTLK Oncobiologics (OTLK) Stock Price, News & Analysis $2.68 +0.28 (+11.41%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncobiologics Stock (NASDAQ:OTLK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncobiologics alerts:Sign Up Key Stats Today's Range$2.38▼$2.6950-Day Range$1.58▼$2.7752-Week Range$0.87▼$8.32Volume3.13 million shsAverage Volume820,678 shsMarket Capitalization$90.14 millionP/E RatioN/ADividend YieldN/APrice Target$9.60Consensus RatingModerate Buy Company Overview Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Read More Oncobiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreOTLK MarketRank™: Oncobiologics scored higher than 43% of companies evaluated by MarketBeat, and ranked 667th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOncobiologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncobiologics has only been the subject of 2 research reports in the past 90 days.Read more about Oncobiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncobiologics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncobiologics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncobiologics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.89% of the float of Oncobiologics has been sold short.Short Interest Ratio / Days to CoverOncobiologics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncobiologics has recently increased by 16.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncobiologics does not currently pay a dividend.Dividend GrowthOncobiologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.89% of the float of Oncobiologics has been sold short.Short Interest Ratio / Days to CoverOncobiologics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncobiologics has recently increased by 16.34%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.54 News SentimentOncobiologics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Oncobiologics this week, compared to 3 articles on an average week.Search Interest17 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows4 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncobiologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Oncobiologics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Oncobiologics is held by institutions.Read more about Oncobiologics' insider trading history. Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter. Email Address OTLK Stock News HeadlinesOncobiologics FY2025 EPS Estimate Increased by HC WainwrightAugust 22 at 2:01 AM | americanbankingnews.comOncobiologics (NASDAQ:OTLK) Given "Neutral" Rating at Chardan CapitalAugust 17, 2025 | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.August 22 at 2:00 AM | Paradigm Press (Ad)Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comOncobiologics (OTLK) to Release Quarterly Earnings on WednesdayAugust 12, 2025 | americanbankingnews.comOutlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseJuly 24, 2025 | globenewswire.comOutlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comOTLK Outlook Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comSee More Headlines OTLK Stock Analysis - Frequently Asked Questions How have OTLK shares performed this year? Oncobiologics' stock was trading at $1.89 at the beginning of 2025. Since then, OTLK shares have increased by 38.9% and is now trading at $2.6250. How were Oncobiologics' earnings last quarter? Oncobiologics, Inc. (NASDAQ:OTLK) released its earnings results on Thursday, August, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02. The firm had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.66 million. When did Oncobiologics' stock split? Shares of Oncobiologics reverse split on the morning of Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Oncobiologics' major shareholders? Top institutional investors of Oncobiologics include Russell Investments Group Ltd. (0.07%) and Group One Trading LLC. Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon and Yezan Munther Haddadin. View institutional ownership trends. How do I buy shares of Oncobiologics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/14/2025Today8/22/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OTLK CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Oncobiologics$9.60 High Price Target$21.00 Low Price Target$3.00 Potential Upside/Downside+298.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.37 million Net MarginsN/A Pretax Margin-2,886.25% Return on EquityN/A Return on Assets-332.30% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-2.17Miscellaneous Outstanding Shares33,570,000Free Float31,957,000Market Cap$80.90 million OptionableOptionable Beta0.26 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:OTLK) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.